Neuphoria Therapeutics Inc.
NEUP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | -$15,663 | $23,874 | $1,071 |
| % Growth | 100% | -165.6% | 2,130.1% | – |
| Cost of Goods Sold | $251 | $331 | $263 | $0 |
| Gross Profit | -$251 | -$15,332 | $23,611 | $0 |
| % Margin | – | 97.9% | 98.9% | 0% |
| R&D Expenses | $5,727 | $8,999,843 | $2,572 | $2,806 |
| G&A Expenses | $0 | $7,767,739 | $0 | $0 |
| SG&A Expenses | $2,574 | $7,767,739 | $1,976 | $4,247 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $332 | $0 | $0 |
| Operating Expenses | $8,301 | $16,767,914 | $4,548 | $7,053 |
| Operating Income | -$8,552 | -$1,133,796 | $19,063 | -$5,983 |
| % Margin | – | 7,238.8% | 79.8% | -558.8% |
| Other Income/Exp. Net | -$6,488 | $287,487 | -$1,267 | $2,862 |
| Pre-Tax Income | -$15,040 | -$846,310 | $17,796 | -$3,121 |
| Tax Expense | -$53 | -$468,164 | -$129 | $19 |
| Net Income | -$14,988 | -$378,146 | $17,925 | -$3,139 |
| % Margin | – | 2,414.3% | 75.1% | -293.2% |
| EPS | -4.41 | -6.77 | 6.55 | -0.008 |
| % Growth | 34.9% | -203.4% | 79,015.7% | – |
| EPS Diluted | -4.41 | -6.77 | 6.55 | -0.008 |
| Weighted Avg Shares Out | 2,246 | 1,623 | 234,012 | 234,012 |
| Weighted Avg Shares Out Dil | 2,246 | 1,623 | 234,012 | 234,012 |
| Supplemental Information | – | – | – | – |
| Interest Income | $142 | -$79 | $13 | $31 |
| Interest Expense | – | $0 | $0 | $0 |
| Depreciation & Amortization | $251 | -$497 | $263 | $0 |
| EBITDA | -$14,789 | -$846,807 | $18,059 | -$3,121 |
| % Margin | – | 5,406.5% | 75.6% | -291.5% |